$9.65
+0.2
(+2.12%)▲
4.56%
Downside
Day's Volatility :6.02%
Upside
1.53%
8.6%
Downside
52 Weeks Volatility :58.0%
Upside
54.05%
Period | Neumora Therapeutics, Inc. | Index (Russel 2000) |
---|---|---|
3 Months | -49.79% | 0.0% |
6 Months | -20.65% | 0.0% |
1 Year | -41.85% | 0.0% |
3 Years | -41.85% | -20.1% |
Market Capitalization | 1.6B |
Book Value | $2.95 |
Earnings Per Share (EPS) | -3.63 |
Wall Street Target Price | 25.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.5% |
Return On Equity TTM | -54.49% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -187.5M |
Diluted Eps TTM | -3.63 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.5 |
EPS Estimate Next Year | -1.63 |
EPS Estimate Current Quarter | -0.55 |
EPS Estimate Next Quarter | -0.66 |
What analysts predicted
Upside of 161.66%
Sell
Neutral
Buy
Neumora Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Neumora Therapeutics, Inc. | -9.22% | -20.65% | -41.85% | -41.85% | -41.85% |
Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Neumora Therapeutics, Inc. | NA | NA | NA | -1.5 | -0.54 | -0.25 | NA | 2.95 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Neumora Therapeutics, Inc. | Buy | $1.6B | -41.85% | NA | 0.0% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Organization | Neumora Therapeutics, Inc. |
Employees | 120 |
CEO | Mr. Paul L. Berns |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$9.65
+2.12%
Keyarch Acquisition Corp
$9.65
+2.12%
Connexa Sports Technologies Inc
$9.65
+2.12%
Us Value Etf
$9.65
+2.12%
First Wave Biopharma Inc
$9.65
+2.12%
Global X Msci Next Emerging
$9.65
+2.12%
Fat Projects Acquisition Corp
$9.65
+2.12%
Ishares Intl Div Growth Etf
$9.65
+2.12%
Corsair Gaming, Inc.
$9.65
+2.12%